Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours (Q33409382)

26 July 2017

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours (English)

1 reference

26 July 2017

Takashi Seto

1

1 reference

26 July 2017

Taito Esaki

2

1 reference

26 July 2017

Fumihiko Hirai

3

1 reference

26 July 2017

Shuji Arita

4

1 reference

26 July 2017

Kaname Nosaki

5

1 reference

26 July 2017

Akitaka Makiyama

6

1 reference

26 July 2017

Takuro Kometani

7

1 reference

26 July 2017

Chinatsu Fujimoto

8

1 reference

26 July 2017

Motoharu Hamatake

9

1 reference

26 July 2017

Hiroaki Takeoka

10

1 reference

26 July 2017

Felix Agbo

11

1 reference

26 July 2017

Xiaojin Shi

12

1 reference

26 July 2017

28 July 2013

1 reference

Cancer Chemotherapy and Pharmacology

26 July 2017

1 reference

26 July 2017

72

1 reference

26 July 2017

3

1 reference

26 July 2017

619-627

1 reference

https://scigraph.springernature.com/pub.10.1007/s00280-013-2234-6

26 July 2017

0 references

cites work

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

New insights into checkpoint kinase 1 in the DNA damage response signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

CaMKII in the cardiovascular system: sensing redox states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

The α2Na+/K+-ATPase is critical for skeletal and heart muscle function in zebrafish

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2234-6

10.1007/S00280-013-2234-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference